SEARCH:   Advanced

Blood, 1 September 2004, Vol. 104, No. 5, pp. 1266-1269. Prepublished online as a Blood First Edition Paper on May 20, 2004; DOI 10.1182/blood-2003-12-4333. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-12-4333v1 104/5/1266    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kuendgen, A. Articles by Gattermann, N. Search for Related Content PubMed PubMed Citation Articles by Kuendgen, A. Articles by Gattermann, N. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid Andrea Kuendgen, Corinna Strupp, Manuel Aivado, Alf Bernhardt, Barbara Hildebrandt, Rainer Haas, Ulrich Germing, and Norbert Gattermann From the Department of Hematology, Oncology, and Clinical Immunology and the Institute of Genetics, Heinrich-Heine-University, Düsseldorf, Germany. Valproic acid (VPA) has been shown to inhibit histone deacetylase activity and to synergize with all-trans retinoic acid (ATRA) in the differentiation induction of acute myelogenous leukemia (AML) blasts in vitro. We treated 18 patients with myelodysplastic syndromes (MDS) and AML secondary to MDS (sAML/MDS) with VPA monotherapy (serum concentrations 346-693 µM [50-100 µg/mL]). Five patients received VPA and ATRA (80 mg/m2/d, days 1-7, every other week). Response according to international working group (IWG) criteria was observed in 8 patients (44%) on VPA monotherapy, including 1 partial remission. Median response duration was 4 months (range, 3-9 months). Four of 5 patients relapsing were treated with VPA + ATRA, 2 of them responding again. Among 5 patients receiving VPA + ATRA from the start, none responded according to IWG criteria, but 1 patient with sAML/MDS achieved a marked reduction in peripheral and marrow blasts. Thus, VPA is of therapeutic benefit for patients with MDS, and ATRA may be effective when added later. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: L. Stimson, V. Wood, O. Khan, S. Fotheringham, and N. B. La Thangue HDAC inhibitor-based therapies and haematological malignancy Ann. Onc., August 1, 2009; 20(8): 1293 - 1302. [Abstract] [Full Text] [PDF] H. M. Prince, M. J. Bishton, and S. J. Harrison Clinical Studies of Histone Deacetylase Inhibitors Clin. Cancer Res., June 15, 2009; 15(12): 3958 - 3969. [Abstract] [Full Text] [PDF] M. Dokmanovic, C. Clarke, and P. A. Marks Histone Deacetylase Inhibitors: Overview and Perspectives Mol. Cancer Res., October 1, 2007; 5(10): 981 - 989. [Abstract] [Full Text] [PDF] A. O. Soriano, H. Yang, S. Faderl, Z. Estrov, F. Giles, F. Ravandi, J. Cortes, W. G. Wierda, S. Ouzounian, A. Quezada, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood, October 1, 2007; 110(7): 2302 - 2308. [Abstract] [Full Text] [PDF] W. Blum, R. B. Klisovic, B. Hackanson, Z. Liu, S. Liu, H. Devine, T. Vukosavljevic, L. Huynh, G. Lozanski, C. Kefauver, et al. Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia J. Clin. Oncol., September 1, 2007; 25(25): 3884 - 3891. [Abstract] [Full Text] [PDF] T. Siitonen, T. Timonen, E. Juvonen, V. Terava, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nylanden, et al. Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes Haematologica, August 1, 2007; 92(8): 1119 - 1122. [Abstract] [Full Text] [PDF] I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood, April 1, 2007; 109(7): 2781 - 2790. [Abstract] [Full Text] [PDF] G. Garcia-Manero Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia Hematology, January 1, 2007; 2007(1): 405 - 411. [Abstract] [Full Text] [PDF] G. Garcia-Manero, H. M. Kantarjian, B. Sanchez-Gonzalez, H. Yang, G. Rosner, S. Verstovsek, M. Rytting, W. G. Wierda, F. Ravandi, C. Koller, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia Blood, November 15, 2006; 108(10): 3271 - 3279. [Abstract] [Full Text] [PDF] G. Cimino, F. Lo-Coco, S. Fenu, L. Travaglini, E. Finolezzi, M. Mancini, M. Nanni, A. Careddu, F. Fazi, F. Padula, et al. Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. Cancer Res., September 1, 2006; 66(17): 8903 - 8911. [Abstract] [Full Text] [PDF] B. Sanchez-Gonzalez, H. Yang, C. Bueso-Ramos, K. Hoshino, A. Quintas-Cardama, V. M. Richon, and G. Garcia-Manero Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor Blood, August 15, 2006; 108(4): 1174 - 1182. [Abstract] [Full Text] [PDF] B. D. Cheson, P. L. Greenberg, J. M. Bennett, B. Lowenberg, P. W. Wijermans, S. D. Nimer, A. Pinto, M. Beran, T. M. de Witte, R. M. Stone, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia Blood, July 15, 2006; 108(2): 419 - 425. [Abstract] [Full Text] [PDF] E. H. Estey Statistical Considerations in Trials of Targeted Therapy: Acute Myelogenous Leukemia as an Example Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 289 - 292. [Full Text] [PDF] D. Cai, Y. Wang, O. G. Ottmann, P. J. Barth, A. Neubauer, and A. Burchert FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment Blood, March 1, 2006; 107(5): 2094 - 2097. [Abstract] [Full Text] [PDF] R. L. Bevins and S. G. Zimmer It's About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells Cancer Res., August 1, 2005; 65(15): 6957 - 6966. [Abstract] [Full Text] [PDF] K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF] N. P. Mongan and L. J. Gudas Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR{beta}2 in breast cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 477 - 486. [Abstract] [Full Text] [PDF] L. De Felice, C. Tatarelli, M. G. Mascolo, C. Gregorj, F. Agostini, R. Fiorini, V. Gelmetti, S. Pascale, F. Padula, M. T. Petrucci, et al. Histone Deacetylase Inhibitor Valproic Acid Enhances the Cytokine-Induced Expansion of Human Hematopoietic Stem Cells Cancer Res., February 15, 2005; 65(4): 1505 - 1513. [Abstract] [Full Text] [PDF] G. Singh, P. H. Driever, and J. W. Sander Cancer risk in people with epilepsy: the role of antiepileptic drugs Brain, January 1, 2005; 128(1): 7 - 17. [Abstract] [Full Text] [PDF] J. D. Licht and D. W. Sternberg The Molecular Pathology of Acute Myeloid Leukemia Hematology, January 1, 2005; 2005(1): 137 - 142. [Abstract] [Full Text] [PDF] E. Hellstrom-Lindberg Update on Supportive Care and New Therapies: Immunomodulatory Drugs, Growth Factors and Epigenetic-Acting Agents Hematology, January 1, 2005; 2005(1): 161 - 166. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020